A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Alzheimer's Disease Cooperative Study (ADCS)

Criteria

Inclusion Criteria:

• Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.

• Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization

Exclusion Criteria:

• Current evidence or history of neurological, psychiatric and any other illness that could contribute to non-Alzheimer's dementia.

• Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations.

• Evidence or history of diabetes mellitus Type 1 or Type 2.

• History or symptoms of autoimmune disorders.